Industry
Biotechnology
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
April 22, 2024 | 3:48 pm
Portfolio Pulse from Benzinga Newsdesk
April 17, 2024 | 5:19 pm
Portfolio Pulse from Benzinga Newsdesk
April 16, 2024 | 2:19 pm
Portfolio Pulse from Benzinga Newsdesk
March 12, 2024 | 3:12 pm
Portfolio Pulse from Benzinga Newsdesk
March 07, 2024 | 10:22 am
Portfolio Pulse from Benzinga Insights
February 22, 2024 | 2:30 pm
Portfolio Pulse from Benzinga Newsdesk
February 22, 2024 | 1:09 pm
Portfolio Pulse from Benzinga Insights
January 31, 2024 | 8:30 pm
Portfolio Pulse from Avi Kapoor
January 26, 2024 | 11:34 am
Portfolio Pulse from Avi Kapoor
January 19, 2024 | 6:05 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.